人肝癌細(xì)胞HepaRG

簡(jiǎn)要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺(tái)，在標(biāo)準(zhǔn)化細(xì)胞庫(kù)建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營(yíng)原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測(cè)等科研產(chǎn)品與服務(wù)。我們秉承對(duì)用戶負(fù)責(zé)的態(tài)度，以對(duì)科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！

更新時(shí)間：2021-05-24

廠商性質(zhì)：生產(chǎn)廠家

瀏覽次數(shù)：392

留言詢價(jià)聯(lián)系我們

詳情介紹

品牌	其他品牌	貨號(hào)	BFN60808919
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現(xiàn)貨
主要用途	僅供科研	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱	人肝癌細(xì)胞HepaRG
貨物編碼	BFN60808919
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運(yùn)輸方式	常溫保溫運(yùn)輸	干冰運(yùn)輸
安全等級(jí)	1
用途限制	僅供科研 2類

培養(yǎng)體系	90%DMEM+10%FBS+1%三抗
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡(jiǎn)介	人肝癌細(xì)胞HepaRG取自女性供體，貼壁培養(yǎng)。
注釋	Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652. Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection. Omics: Deep proteome analysis. Omics: Membrane proteome analysis. Omics: miRNA expression profiling. Omics: Transcriptome analysis. Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.
基因突變	/
HLA信息	/
STR信息	/
參考文獻(xiàn)	PubMed=12432097; DOI=10.1073/pnas.232137699 Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002) PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003 Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168:66-73(2007) PubMed=17393521; DOI=10.1002/hep.21536 Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957-967(2007) Patent=US7456018 Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S. Human hepatoma lines, methods for obtaining same and uses thereof. Patent number US7456018, 25-Nov-2008 PubMed=20228232; DOI=10.1124/dmd.109.031831 Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab. Dispos. 38:988-994(2010) PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13 Marion M.-J., Hantz O., Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol. Biol. 640:261-272(2010) PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004 Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V. Critical selection of reliable reference genes for gene expression study in the HepaRG cell line. Biochem. Pharmacol. 81:1255-1261(2011) PubMed=22568886; DOI=10.1517/17425255.2012.685159 Andersson T.B., Kanebratt K.P., Kenna J.G. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin. Drug Metab. Toxicol. 8:909-920(2012) PubMed=22594799; DOI=10.3109/13813455.2012.683442 Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B. The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism. Arch. Physiol. Biochem. 118:102-111(2012) PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008 Antherieu S., Chesne C., Li R., Guguen-Guillouzo C., Guillouzo A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. In Vitro 26:1278-1285(2012) PubMed=22857383; DOI=10.1186/1477-5956-10-47 Sokolowska I., Dorobantu C., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C. Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells. Proteome Sci. 10:47-47(2012) PubMed=23887712; DOI=10.1038/ncomms3218 Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4:2218-2218(2013) PubMed=26160117; DOI=10.1093/toxsciv136 Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K. Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication. Toxicol. Sci. 147:412-424(2015) PubMed=26694163; DOI=10.1371/journal.pone.0144924 Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M. Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE 10:E0144924-E0144924(2015) PubMed=27169750; DOI=10.1038ep24709 Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci. Rep. 6:24709-24709(2016) PubMed=27780834; DOI=10.1124/dmd.116.072603 van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R. Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells. Drug Metab. Dispos. 45:56-67(2017) PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2 Ni Y., Urban S. Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes. Methods Mol. Biol. 1540:15-25(2017) PubMed=28904299; DOI=10.2131/jts.42.641 Tomida T., Ishimura M., Iwaki M. A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis. J. Toxicol. Sci. 42:641-650(2017)

青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺(tái)，在標(biāo)準(zhǔn)化細(xì)胞庫(kù)建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營(yíng)原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測(cè)等科研產(chǎn)品與服務(wù)。我們秉承對(duì)用戶負(fù)責(zé)的態(tài)度，以對(duì)科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！